SCHEMBL378044

SCHEMBL378044

CC(=O)N1CCCN(c2ccc(C=O)cc2)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 0.62
TRIM33 Q9UPN9 1/20 0.62
ALDH1A1 P00352 6/20 0.60
KDM4E B2RXH2 2/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
GFER P55789 3/20 0.58
CASP6 P55212 1/20 0.58
MAPT P10636 6/20 0.54
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
CYP17A1 P05093 3/20 0.47
CYP21A2 P08686 3/20 0.47
CYP11B1 P15538 3/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
PTGS2 P35354 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP19A1 P11511 1/20 0.46
GAA P10253 2/20 0.46
ALOX15 P16050 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL377648 0.94 GFER (0.65) TRIM24TRIM33ALDH1A1KDM4ESMN1; SMN2
SCHEMBL7180854 0.82 TRIM24 (0.91) TRIM24TRIM33ALDH1A1KDM4ESMN1; SMN2
SCHEMBL3027791 0.81 GFER (0.61) ALDH1A1KDM4ESMN1; SMN2GFERCASP6
SCHEMBL3548441 0.81 GFER (0.87) ALDH1A1KDM4ESMN1; SMN2GFERCASP6
SCHEMBL17923025 0.81 GFER (0.65) ALDH1A1KDM4ESMN1; SMN2GFERCASP6
SCHEMBL15707566 0.81 AKR1C3 (0.65) ALDH1A1GFERCASP6MAPTMEN1
SCHEMBL4756395 0.79 TRIM24 (0.61) TRIM24TRIM33ALDH1A1KDM4ESMN1; SMN2
SCHEMBL13009470 0.79 MAPT (0.67) ALDH1A1KDM4ESMN1; SMN2GFERCASP6
SCHEMBL13061748 0.79 MAPT (0.69) ALDH1A1KDM4ESMN1; SMN2GFERCASP6
SCHEMBL2507401 0.78 GFER (0.57) ALDH1A1KDM4ESMN1; SMN2GFERCASP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2408454-B1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP (CA) 2024-07-24 EP disclosed
US-11407719-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2022-08-09 US disclosed
US-20210070716-A1 ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2021-03-11 US disclosed
US-10882828-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2021-01-05 US disclosed
US-20190119222-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2019-04-25 US disclosed
US-10131640-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2018-11-20 US disclosed
US-20160137613-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2016-05-19 US disclosed
US-9238640-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2016-01-19 US disclosed
WO-2013175281-A1 USE OF SUBSTITUTED 2-PHENYL-3H-QUINAZOLIN-4-ONES AND ANALOGS FOR INHIBITING BROMODOMAIN AND EXTRA TERMINAL DOMAIN (BET) PROTEINS RVX THERAPEUTICS INC. (CA) 2013-11-28 WO disclosed
US-20130281399-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION RVX THERAPEUTICS INC. (CA) 2013-10-24 US disclosed
US-20120040954-A1 NOVEL ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2012-02-16 US disclosed
EP-2408454-A2 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2012-01-25 EP disclosed
WO-2010106436-A2 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11407719-B2 Anti-inflammatory agents VCAM1, ICAM1, IL6 TRIM24 2111/4885TRIM33 3495/4885ALDH1A1 587/4885
US-20160137613-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 TRIM24 2158/4885TRIM33 3360/4885ALDH1A1 650/4885
US-20130281399-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION PHKB, BAZ2A, EP300 TRIM24 880/4885TRIM33 879/4885ALDH1A1 3920/4885
US-10882828-B2 Anti-inflammatory agents VCAM1, ICAM1, IL6 TRIM24 2111/4885TRIM33 3495/4885ALDH1A1 587/4885
US-20210070716-A1 ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 TRIM24 2111/4885TRIM33 3495/4885ALDH1A1 587/4885
US-10131640-B2 Anti-inflammatory agents VCAM1, ICAM1, IL6 TRIM24 2111/4885TRIM33 3495/4885ALDH1A1 587/4885
US-20190119222-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 TRIM24 2158/4885TRIM33 3360/4885ALDH1A1 650/4885
US-20120040954-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 TRIM24 2158/4885TRIM33 3360/4885ALDH1A1 650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.